Limits...
TFIIB-related factor 2 over expression is a prognosis marker for early-stage non-small cell lung cancer correlated with tumor angiogenesis.

Lu M, Tian H, Yue W, Li L, Li S, Qi L, Hu W, Gao C, Si L - PLoS ONE (2014)

Bottom Line: Intratumoral microvessel density (MVD) was measured by counting CD-34 positive immunostained endothelial cells.In addition, univariate and multivariate analysis demonstrated that BRF2 protein over-expression and high MVD were significantly associated with tumor relapse.Although BRF2 overexpression and high MVD indicated poor 5-year overall survival (p = 0.004 and p = 0.019, respectively), multivariate analysis demonstrated that only BRF2 overexpression was an independent prognostic factor for unfavorable overall survival (P = 0.021).

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.

ABSTRACT

Background: The aim of this study was to examine BRF2 expression in patients with non-small cell lung cancer (NSCLC) and explore the relationship of BRF2 protein with clinicopathologic factors, tumor angiogenesis and prognosis.

Methods: Both BRF2 protein and intratumoral microvessels were examined by immunohistochemical staining in 107 non-small cell lung cancer patients. Intratumoral microvessel density (MVD) was measured by counting CD-34 positive immunostained endothelial cells. Western blot and RT-PCR analyses were utilized to investigate the BRF2 expression status in tissues.

Results: A notably higher level of BRF2 expression was found in NSCLC tissues at protein levels. In addition, univariate and multivariate analysis demonstrated that BRF2 protein over-expression and high MVD were significantly associated with tumor relapse. Although BRF2 overexpression and high MVD indicated poor 5-year overall survival (p = 0.004 and p = 0.019, respectively), multivariate analysis demonstrated that only BRF2 overexpression was an independent prognostic factor for unfavorable overall survival (P = 0.021).

Conclusions: BRF2 is a promising biomarker to identify individuals with poor prognostic potential and a possible target for anti-angiogenic therapy for patients with early-stage NSCLC.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier survival curves of patients stratified according to histology type.(a): squamous cell carcinoma. (b): adenocarcinoma.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3921153&req=5

pone-0088032-g004: Kaplan-Meier survival curves of patients stratified according to histology type.(a): squamous cell carcinoma. (b): adenocarcinoma.

Mentions: We further analyzed the prognostic significance of BRF2 protein in selective patient subgroups stratified according to histology type of NSCLC. Univariate analysis demonstrated that the overall 5-year survival rate of patients with BRF2 protein high expression was significantly lower than that of the remaining patients among squamous cell carcinoma, and we also found such a trend in adenocarcinoma, despite the statistical analysis does not make sense; (P = 0.007 and P = 0.130, respectly; Fig. 4).


TFIIB-related factor 2 over expression is a prognosis marker for early-stage non-small cell lung cancer correlated with tumor angiogenesis.

Lu M, Tian H, Yue W, Li L, Li S, Qi L, Hu W, Gao C, Si L - PLoS ONE (2014)

Kaplan-Meier survival curves of patients stratified according to histology type.(a): squamous cell carcinoma. (b): adenocarcinoma.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3921153&req=5

pone-0088032-g004: Kaplan-Meier survival curves of patients stratified according to histology type.(a): squamous cell carcinoma. (b): adenocarcinoma.
Mentions: We further analyzed the prognostic significance of BRF2 protein in selective patient subgroups stratified according to histology type of NSCLC. Univariate analysis demonstrated that the overall 5-year survival rate of patients with BRF2 protein high expression was significantly lower than that of the remaining patients among squamous cell carcinoma, and we also found such a trend in adenocarcinoma, despite the statistical analysis does not make sense; (P = 0.007 and P = 0.130, respectly; Fig. 4).

Bottom Line: Intratumoral microvessel density (MVD) was measured by counting CD-34 positive immunostained endothelial cells.In addition, univariate and multivariate analysis demonstrated that BRF2 protein over-expression and high MVD were significantly associated with tumor relapse.Although BRF2 overexpression and high MVD indicated poor 5-year overall survival (p = 0.004 and p = 0.019, respectively), multivariate analysis demonstrated that only BRF2 overexpression was an independent prognostic factor for unfavorable overall survival (P = 0.021).

View Article: PubMed Central - PubMed

Affiliation: Department of Thoracic Surgery, Qilu Hospital, Shandong University, Jinan, P. R. China.

ABSTRACT

Background: The aim of this study was to examine BRF2 expression in patients with non-small cell lung cancer (NSCLC) and explore the relationship of BRF2 protein with clinicopathologic factors, tumor angiogenesis and prognosis.

Methods: Both BRF2 protein and intratumoral microvessels were examined by immunohistochemical staining in 107 non-small cell lung cancer patients. Intratumoral microvessel density (MVD) was measured by counting CD-34 positive immunostained endothelial cells. Western blot and RT-PCR analyses were utilized to investigate the BRF2 expression status in tissues.

Results: A notably higher level of BRF2 expression was found in NSCLC tissues at protein levels. In addition, univariate and multivariate analysis demonstrated that BRF2 protein over-expression and high MVD were significantly associated with tumor relapse. Although BRF2 overexpression and high MVD indicated poor 5-year overall survival (p = 0.004 and p = 0.019, respectively), multivariate analysis demonstrated that only BRF2 overexpression was an independent prognostic factor for unfavorable overall survival (P = 0.021).

Conclusions: BRF2 is a promising biomarker to identify individuals with poor prognostic potential and a possible target for anti-angiogenic therapy for patients with early-stage NSCLC.

Show MeSH
Related in: MedlinePlus